文献速递泌尿男性生殖肿瘤

CheckMate 9ER 试验:纳武利尤单抗联合卡博替尼对比舒尼替尼一线治疗晚期肾细胞癌的患者报告结局

Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2022-01-12

CheckMate 9ER 是一项在 18 个国家 125 个中心开展的开放标签随机 3 期试验,比较纳武利尤单抗联合卡博替尼与舒尼替尼一线治疗晚期肾细胞癌。患者报告结局分析显示,联合组在 FKSI-19 总分、疾病相关症状、EQ-5D-3L VAS 及 UK 效用指数上均优于舒尼替尼组,并显著延迟 FKSI-19 总分的临床意义恶化。

要点

  • 联合组 FKSI-19 总分变化优于舒尼替尼组,治疗差异 2.38(95%CI 1.20-3.56)。
  • 联合组 FKSI-19 总分首次恶化 HR 0.70(95%CI 0.56-0.86),确认恶化 HR 0.63(95%CI 0.50-0.80)。
  • 联合组 EQ-5D-3L VAS 变化优于舒尼替尼组,治疗差异 3.48(95%CI 1.58-5.39)。

核心结论

  • 纳武利尤单抗联合卡博替尼较舒尼替尼维持或改善患者报告结局,并显著延迟患者报告结局评分的恶化时间。

研究设计与样本

  • 开放标签、随机、3 期试验,在 18 个国家 125 个癌症中心、泌尿中心及医院开展。
  • 入组既往未治疗、含透明细胞成分的晚期肾细胞癌患者,Karnofsky 体能状态评分 70% 或以上,且有可用肿瘤组织。
  • 323 例随机分配至纳武利尤单抗 240 mg 每 2 周静脉给药联合口服卡博替尼 40 mg 每日一次,328 例分配至口服舒尼替尼 50 mg 每日一次、6 周周期中用药 4 周。
  • 患者报告结局为预设探索性终点,在基线及每 6 周至第 115 周的共同时间点分析,采用 FKSI-19、EQ-5D-3L VAS 和 UK 效用指数评估。
  • 患者报告结局在意向治疗人群中分析,基线变化采用混合模型重复测量,并分析首次及确认恶化事件的时间。

主要发现

  • 基线时两组症状负担均低,FKSI-19 疾病相关症状版本 1 平均分联合组为 30.24(SD 5.19),舒尼替尼组为 30.06(SD 5.03)。
  • FKSI-19 总分变化联合组优于舒尼替尼组,治疗差异 2.38(95%CI 1.20-3.56),名义 p<0.0001,效应量 0.33(95%CI 0.17-0.50)。
  • FKSI-19 疾病相关症状版本 1 变化联合组优于舒尼替尼组,治疗差异 1.33(95%CI 0.84-1.83),名义 p<0.0001,效应量 0.45(95%CI 0.28-0.61)。
  • EQ-5D-3L VAS 变化联合组优于舒尼替尼组,治疗差异 3.48(95%CI 1.58-5.39),名义 p=0.0004,效应量 0.30(95%CI 0.14-0.47)。
  • FKSI-19 总分首次恶化 HR 0.70(95%CI 0.56-0.86),名义 p=0.0007;确认恶化 HR 0.63(95%CI 0.50-0.80),名义 p=0.0001。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the CheckMate 9ER trial, patients with advanced renal cell carcinoma who received first-line nivolumab plus cabozantinib had significantly better progression-free survival compared with those given sunitinib. In this study, we aimed to describe the patient-reported outcome (PRO) results from CheckMate 9ER. METHODS: In this open-label, randomised, phase 3 trial done in 125 cancer centres, urology centres, and hospitals across 18 countries, patients aged 18 years or older with previously untreated advanced renal cell carcinoma with a clear-cell component, a Karnofsky performance status of 70% or more, and available tumour tissue were randomly assigned (1:1) via interactive response technology to nivolumab 240 mg intravenously every 2 weeks plus oral cabozantinib 40 mg per day, or oral sunitinib 50 mg per day monotherapy for 4 weeks in 6-week cycles. The primary endpoint of progression-free survival was reported previously. PROs were analysed as prespecified exploratory endpoints at common timepoints (at baseline and every 6 weeks) until week 115. Disease-related symptoms were evaluated using the 19-item Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI-19), and global health status was assessed with the three-level EQ-5D (EQ-5D-3L) visual analogue scale (VAS) and UK utility index. PRO analyses were done in the intention-to-treat population. Change from baseline was assessed using mixed-model repeated measures. A time-to-deterioration analysis was done for first and confirmed deterioration events. This study is registered with ClinicalTrials.gov, NCT03141177, and is closed to recruitment. FINDINGS: Between Sept 11, 2017, and May 14, 2019, 323 patients were randomly assigned to nivolumab plus cabozantinib and 328 to sunitinib. Median follow-up was 23·5 months (IQR 21·0-26·5). At baseline, patients in both groups reported low symptom burden (FKSI-19 disease-related symptoms version 1 mean scores at baseline were 30·24 [SD 5·19] for the nivolumab plus cabozantinib group and 30·06 [5·03] for the sunitinib group). Change from baseline in PRO scores indicated that nivolumab plus cabozantinib was associated with more favourable outcomes versus sunitinib (treatment difference 2·38 [95% CI 1·20-3·56], nominal p<0·0001, effect size 0·33 [95% CI 0·17-0·50] for FKSI-19 total score; 1·33 [0·84-1·83], nominal p<0·0001, 0·45 [0·28-0·61] for FKSI-19 disease-related symptoms version 1; 3·48 [1·58-5·39], nominal p=0·0004, 0·30 [0·14-0·47] for EQ-5D-3L VAS; and 0·04 [0·01-0·07], nominal p=0·0036, 0·25 [0·08-0·41] for EQ-5D-3L UK utility index), reaching significance at most timepoints. Nivolumab plus cabozantinib was associated with decreased risk of clinically meaningful deterioration for FKSI-19 total score compared with sunitinib (first deterioration event hazard ratio 0·70 [95% CI 0·56-0·86], nominal p=0·0007; confirmed deterioration event 0·63 [0·50-0·80], nominal p=0·0001). INTERPRETATION: PROs were maintained or improved with nivolumab plus cabozantinib versus sunitinib. Compared with sunitinib, nivolumab plus cabozantinib significantly delayed time to deterioration of patient-reported outcome scores. These results suggest a benefit for nivolumab plus cabozantinib compared with sunitinib in the treatment of patients with advanced renal cell carcinoma. FUNDING: Bristol Myers Squibb.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Cella D, Motzer RJ, Suarez C, et al. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. Lancet Oncol. 2022. PMID: 35032437. doi:10.1016/S1470-2045(21)00693-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。